ACRPO  >> Vol. 5 No. 3 (July 2016)

    Advances of Human Epididymis Protein 4 in Clinical Application

  • 全文下载: PDF(392KB) HTML   XML   PP.39-44   DOI: 10.12677/ACRPO.2016.53004  
  • 下载量: 1,078  浏览量: 3,076   科研立项经费支持


王雅菲,托 娅,王丽娟:内蒙古医科大学附属医院检验科,内蒙古 呼和浩特

HE4卵巢癌肺癌恶性胸腔积液HE4 Ovarian Cancer Lung Cancer Malignant Pleural Effusion


人附睾蛋白4 (human epididymis 4, HE4)是近年来新发现的肿瘤标志物,血清HE4水平作为卵巢癌诊断、疗效评估及预后判断的新指标已经逐渐应用于临床。现有研究显示HE4在肺癌患者血清和恶性胸腔积液患者胸水中呈现较高水平表达,提示其在肺癌诊断、预后评估方面的良好作用。本文就HE4在卵巢癌及肺癌的临床应用作一综述。

Human epididymis protein 4 (HE4) as a novel tumor marker is found in recent years. Serum HE4 level as a new indicator for the diagnosis, therapeutic evaluation and prognosis of ovarian cancer has been applied to the clinical gradually. The existing research shows serum HE4 of patients with lung cancer and HE4 in pleural effusion of patients with malignant pleural effusion presented higher levels of expression, suggesting a good role in the diagnosis and the prognosis evaluation of lung cancer. This article reviews the research of HE4 in clinical application of ovarian cancer and lung cancer.

王雅菲, 托娅, 王丽娟. 人附睾蛋白4临床应用研究进展[J]. 亚洲肿瘤科病例研究, 2016, 5(3): 39-44.


[1] Barbieri, R.L. (2010) In Women Who Have a Pelvic Mass Have You Tried This New Ovarian Cabiomarker? OBG Management, 22, 8-12.
[2] Kirchhoff, C., Habben, I., Ivell, R., et al. (1991) A Major Human Epididymis-Specific cDNA Encodes a Protein with Sequence Homology to Extracellular Proteinase Inhibitors. Biology of Reproduction, 45, 350-357.
[3] Bingle, L., Singleton, V. and Bingle, C.D. (2002) The Putative Ovarian Tumour Marker Gene HE4 (WFDC2), Is Expressed in Normal Tissues and Undergoes Complex Alternative Splicing to Yield Multiple Protein Isoforms. Oncogene, 21, 2768-2773.
[4] Bingle, L., Cross, S.S., High, A.S., et al. (2006) WFDC2(HE4): A Protential Role in the Innate Immunity of The Oral Cavity and Respiratory Tract and Development of Adenocarcinomas of the Lung. Respiratory Research, 7, 61.
[5] Gao, L., Cheng, H.Y., Dong, L., et al. (2011) The Role of HE4 in Ovarian Cancer: Inhibiting Tumour Cell Proliferation and Metastasis. Journal of International Medical Research, 39, 1645-1660.
[6] Clauss, A., Ng, V., Liu, J., et al. (2010) Over Expression of Elafin in Ovarian Carcinoma Is Driven by Genomic Gains And Activation of the Nuclear Factor Kappa B Pathway And Is Associated with Poor Overall Surviva. Neoplasia, 12, 161-172.
[7] Lin, Y., Bai, L., Chen, W., et al. (2010) The NF kappaB Activation Pathways, Emerging Molecular Targets for Cancer Prevention and Therapy. Expert Opinion on Therapeutic Targets, 14, 45-55.
[8] Galgano, M.T., Hampton, G.M., Frierson Jr., H.F. (2006) Comprehensive Analysis of HE4 Expression in Normal and Malignant Human Tissues. Modern Pathology, 19, 847-853.
[9] Karlsen, N.S., Karlsen, M.A., Hogdall, C.K., et al. (2014) HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review. Cancer Epidemiology, Biomarkers & Prevention, 23, 2285-2295.
[10] Moore, R.G., Brown, A.K., Miller, M.C., et al. (2008) The Use of Multiple Novel Tumor Biomarkers for the Detection of Ovarian Carcinoma in Patients with Pelvic Mass. Gynecologic Oncology, 108, 402-408.
[11] Holcomb, K., Vucetic, Z., Miller, M.C., et al. (2011) Human Epididymis Protein 4 Offers Superior Specificity in the Differentiation of Benign and Malignant Adnexal Masses in Premenopausal Women. American Journal of Obstetrics & Gynecology, 205, 358-366.
[12] Karisen, M.A., Sandhu, N., Hogdall, C., et al. (2012) Evaluation of HE4, CA125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) as Diagnostic Tools of Epithelial Ovarian Cancer in Patients with a Pelvic Mass. Gynecologic Oncology, 127, 379-383.
[13] FDA (2014) US Foodand Drug Administration.
[14] 王瑞红. 人附睾分泌蛋白4和CA125对卵巢癌的联合诊断价值[J]. 国际检验医学杂志, 2014, 35(1): 103-104.
[15] 刘倩, 郭健. HE4 和 CA125 监测老年卵巢癌转归的价值[J]. 标记免疫分析与临床, 2011, 18(6): 374-379.
[16] 石华, 罗蔚, 李文胜, 等. 血清人附睾上皮分泌蛋白水4平检测在卵巢癌的应用价值[J]. 实用妇产科杂志, 2015, 31(4): 267-269.
[17] 程洪艳, 刘亚南, 叶雪, 等. 血清人附睾分泌蛋白4(HE4)和CA125在卵巢癌患者手术及化疗前后的变化[J]. 中国妇产科临床杂志, 2011, 12(3): 212-215.
[18] 蔡斌, 刘雪莲, 杨懿霞, 等. 913例健康体检女性血清HE4水平分布的初步观察[J]. 实用妇产科杂志, 2012, 28(12): 1045-1049.
[19] 刘静, 曲芃芃. ROMA指数在卵巢癌诊断中临床价值的Meta分析[J]. 实用妇产科杂志, 2015, 31(3): 209-213.
[20] 王坤, 玉萍, 郭亚琼. ROMA指数在卵巢恶性肿瘤诊断中的应用价值[J]. 标记免疫分析与临床, 2015, 22(7): 666-668.
[21] 高岚, 许泼实, 张福明. 血清HE4、CA-125及ROMA指数在卵巢癌诊断中的价值评价[J]. 医药论坛杂志, 2015, 36(9): 8-9.
[22] 邓拥军, 郭秋霞. HE4、CA-125、ROMA联合应用诊断卵巢良性与恶性肿瘤的作用[J]. 湖北中医药大学学报, 2015, 17(1): 102-104.
[23] 雅培. 中国人群卵巢癌风险评估进展[R]. 全国检验医师大会, 2013.
[24] Jemal, A., Siegel, R. and Xu, J. (2010) Cancer Statistics. CA: A Cancer Journal for Clinicians, 60, 277-300.
[25] Molina, J.R., Yang, P., Cassivi, S.D., et al. (2008) Non-Small Cell Lung Cancer: Epidemiology, Risk Factor, Treatment, and Survivorship. Mayo Clinic Proceedings, 83, 584-594.
[26] Mulshine, J.L. and Sullivan, D.C. (2005) Clinical Practice Lung Cancer Screening. The New England Journal of Medicine, 352, 2714-2720.
[27] Yamashita, S., Tokuishi, K., Hashimoto, T., et al. (2011) Prognostic Significance of HE4 Expression in Pulmonary Adenocarcinoma. Tumor Biology, 32, 265-271.
[28] Iwahori, K., Suzuki, H., Kishi, Y., et al. (2012) Serum HE4 as a Diagnostic and Prognostic Marker for Lung Cancer. Tumor Biology, 33, 1141-1149.
[29] Tokuishi, K., Yamashita, S., Ohbo, K., et al. (2012) Splice Variant HE4-V3 Expression Is Associated with Favorable Prognosis in Pulmonary Adenocarcinoma. Tumor Biology, 33, 103-109.
[30] 肖然, 胡昊昀, 王瑞, 等. 血清肿瘤标志物 HE4 检测在肺癌诊断中的应用价值探讨[J]. 检验医学, 2014, 29(9): 893-896.
[31] 于飞, 王倩, 钟殿胜, 等. 血清人附睾蛋白 4 检测对肺癌的诊断意义[J]. 天津医药, 2014, 42(2): 116-118.
[32] 薛霞, 杨凡, 单咏梅, 等. 血清人附睾蛋白4检测在肺癌诊断中的意义[J]. 实用检验医师杂志, 2013, 5(2): 96-98.
[33] Elsammak, M.Y., Attia, A., Hassan, H.A., et al. (2012) Evaluation of Pleural Fluid Human Epididymis 4 (HE4) as a Marker of Malignant Pleural Effusion. Tumor Biology, 33, 1701-1707.
[34] Hegmans, J.P., Veltman, J.D., Fung, E.T., et al. (2009) Protein Profiling of Pleural Effusions to Identify Malignant Pleural Mesothelioma Using SELDI-TOF MS. Technology in Cancer Research & Treatment, 8, 323-332.